PA-EXONE
22.9.2020 14:02:08 CEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today debuted a concept rendering of the InnoventPro, a preview of the world’s most advanced entry-level binder jetting system for printing metals, ceramics and composites.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005243/en/
The InnoventPro will be a major upgrade of the Innovent+, the world’s best-selling metal binder jetting system since 2016. The InnoventPro will offer two new build sizes, a 3-liter and a 5-liter, with print speeds topping 700 cc/hour. The updated system is aimed at academics, researchers, and a full spectrum of manufacturers, from machine and MIM shops to high-volume producers, who want to produce metal parts quickly, affordably and sustainably.
“Customers around the world already love the Innovent+, and based on their feedback, we’re going to give them an updated entry-level system that’s bigger, faster and smarter than ever,” said John Hartner, ExOne CEO.
Siemens Digital Industries will serve as an Industry 4.0 collaboration partner on the production version of the machine, to be unveiled in the second half of 2021. An incentive program for the InnoventPro will be offered to customers who buy an Innovent+ prior to commercial availability of the new system. Learn more at www.exone.com/InnoventPro
Raising the bar in binder jetting
Binder jetting is a groundbreaking 3D printing process that uses a digital file to quickly inkjet a binder into a bed of powder particles — metal, sand or ceramic — creating a solid part one layer at a time. When printing metals, the final part must be sintered in order to fuse the particles together into a solid object.
Binder jetting is a sustainable method of manufacturing that reduces material waste to less than 5%, saves energy by consolidating many assembled parts and processes into one, and can deliver end-use products that are 30-40% lighter — for more efficient cars, planes and military equipment.
Importantly, the new InnoventPro will feature the same recirculating printhead modules used on the X1 25Pro® and X1 160Pro™ metal 3D printers, allowing users to easily scale up from R&D to high-volume production.
The recirculating printhead also enables ExOne’s pioneering move to offer particulate binders as an option on a commercial binder jetting system. The ExOne research team has been 3D printing a variety of nanoparticles suspended in its binders for years.
All-New Class of NanoFuse Binders
First patented in 2018 , with related patents pending worldwide, ExOne’s “inkjet-printable nanoparticle suspensions” are slated for commercial deployment in the InnoventPro. This all-new class of ExOne NanoFuse binders advances the field of binder jet 3D printing in critical ways.
Because nanoparticles fill in the interstices between powder bed particles and can bond at lower temperatures, they enable stronger green parts. In turn, this enables 3D printing of larger parts and finer features, delivering sharper corners and edges. These new binders can also improve the resolution and sinterability of high-demand metals, such as copper and aluminum.
Rick Lucas, ExOne CTO and VP, New Markets, said the InnoventPro and new NanoFuse binders show how ExOne continues to lead the way in commercial development of binder jetting.
“Just as the current Innovent+ served as the proving ground for our patented Triple ACT system, which now delivers industry-leading quality in metal binder jetting, the InnoventPro will offer groundbreaking new features in a commercial system,” Lucas said. “Our patented approach to 3D printing particulate inks in a print bed is opening new doors in binder jetting.”
ExOne’s patented Triple ACT is a critical advanced compaction technology that, depending on material, delivers industry-leading final part density of 97+%, dimensional tolerances in the range of <1%-2.5%, and high consistency, with part variation of just 0.3% across the print bed.
Triple ACT has been so effective that it has also sped up ExOne’s qualification of new materials. ExOne binder jet systems now process more than 20 metal, ceramic and composite materials , with single-alloy metals making up more than half of those offerings. NanoFuse binders are expected to expand that material range and improve sintering dynamics.
A webinar about NanoFuse will be held at 9 a.m. on Wednesday, Nov. 4. Details are available at https://tinyurl.com/NanoFuseWebinar .
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005243/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
